Wuxi Bio releases earnings today; are short-term opportunities emerging under oversold signals?

Earnings will be released today (the 24th), with the stock price rebounding over 2% before the results, fluctuating between HKD 32.72 and HKD 33.66 during trading. The current share price has consecutively fallen below several key moving averages, including the 10-day MA (HKD 34.8), the 30-day MA (HKD 37.52), and the 60-day MA (HKD 36.95), often referred to as the 'lifeline.' Short-, medium-, and long-term moving averages have formed a bearish alignment, showing an obvious overall downtrend. However, after the rapid adjustment in the earlier period, the stock price is gradually approaching the core technical support zone. After market pessimism has been fully released, some contrarian technical indicators are beginning to emerge, and the window for short-term technical rebound speculation is gradually opening.

From a fundamental perspective, the company's earlier positive profit alert forecasted total revenue for 2025 to reach RMB 21.79 billion, a year-over-year increase of 16.7%; gross margin rising by 5 percentage points year-over-year to 46%, corresponding to an adjusted gross profit of approximately RMB 10.638 billion, up 25.5% year-over-year; net profit attributable to shareholders is expected at RMB 4.908 billion, growing 46.3% year-over-year; non-IFRS adjusted net profit excluding non-recurring gains/losses is estimated at RMB 6.586 billion, increasing 22% year-over-year.

Technical indicators show typical characteristics of 'signal divergence in an oversold state': oscillation indicators have entered deep oversold territory, with both stochastic oscillators and Williams %R issuing clear buy signals, indicating that short-term selling pressure is nearing exhaustion; trend-following indicators also signal buying, hinting at brewing momentum for a price reversal. Meanwhile, trend-based indicators remain largely bearish: momentum oscillators and rate-of-change indicators maintain sell signals, while the Average Directional Index is in a neutral range, suggesting that though downward trend momentum has weakened somewhat, no fundamental reversal has yet occurred. The conflicting signals between oscillation and trend indicators suggest the market is currently in the process of forming a short-term bottom.

In terms of key price levels, the first support lies at HKD 30.8; if broken, it may further test the second support at HKD 29.1, which serves as the critical defense line for judging the depth of this pullback. The first resistance above is near HKD 35, coinciding with the 10-day MA, representing the primary pressure point for a short-term rebound. A successful breakout could lead to a challenge of the second resistance at HKD 38.9, located where the 30-day MA overlaps with the lower edge of a previous consolidation platform, where selling pressure is expected to intensify.

Overall, Wuxi Bio’s current movement shows characteristics of a 'bearish trend but short-term oversold' state: on one hand, the bearish alignment of MAs and trend indicators confirms the existence of a medium-term downtrend; on the other hand, the deeply oversold condition combined with buy signals from certain oscillation indicators significantly increases the likelihood of a technical rebound near key support levels. For professional investors, the current price has entered a high-risk, high-reward observation zone. Trading strategies could consider using HKD 29.1 as the ultimate stop-loss line, and lightly positioning for a short-term rebound when the price approaches HKD 30.8 support with signs of stabilization, targeting the HKD 35 resistance level. It should be noted this is a bounce play in an oversold scenario, not a trend reversal signal, so strict position control is necessary.

In terms of derivatives market data from March 19 to 23, the street volume of call warrants initially stabilized before rising, increasing from 33.81 million units at the beginning to 37.45 million units, with a cumulative increase of about 10.8%. The street volume of put warrants remained consistently low, staying within an extremely low range of 0.06-0.09 million units. For bull and bear warrants, the street volume of bull warrants fell continuously from 58.13 million units to 48.17 million units, with a cumulative decrease of approximately 17%, while the street volume of bear warrants fluctuated stably within a narrow range of 1.6-1.7 million units.

For investors who are bullish on Wuxi Bio, they can focus on higher-leverage call warrants and bull contracts. Among these, $CT-WUXI@EC2611A.C (22887.HK)$with an exercise price of HK$38.86, offers an effective leverage of approximately 3.4 times. Its premium and implied volatility are relatively the lowest among products with similar terms, reducing the cost of time value decay, making it suitable for capturing a potential rebound. If you believe in a strong rebound and want to seek higher returns at a lower cost, consider the product with an actual leverage of around 7.4 times, $JP#WUXI RC2708E.C (56310.HK)$which has a stop-loss level set at HK$30, providing a buffer of about 7% from the current price, along with a relatively low premium; another option is $UB#WUXI RC2609B.C (56708.HK)$offering an actual leverage of about 7.7 times, with the lowest premium among similar products, providing relatively better downside protection.

Conversely, if you are bearish on the stock price, you may consider deploying put warrants or bear contracts.$HU-WUXI@EP2606A.P (21980.HK)$With an exercise price of HK$26, this provides an effective leverage of about 4.8 times and serves as a high-leverage tool to capture downward opportunities. For investors who are bearish on the outlook, $JP#WUXI RP2812A.P (61915.HK)$this is a more stable choice, with its stop-loss level set at HK$45, offering ample safety margin from the current price, actual leverage of about 2.94 times, and the lowest premium among similar products, effectively hedging against further declines in the underlying stock.

$WUXI APPTEC (02359.HK)$The stock surged over 8% after earnings. Do you think Wuxi Bio will perform well after today's earnings announcement? Feel free to share your thoughts in the comments section. For more market analysis, stay tuned to 'HK Stock Jenny' daily updates!$Hang Seng Index (800000.HK)$$Biotechnology (LIST22911.HK)$

Reminder: This article does not constitute any investment advice.

This article is for reference only and does not constitute any investment advice. The market data, opinions, and analysis contained herein may change at any time without prior notice. We are not responsible for any loss or damage caused by reliance on the information in this article. Technical analysis only shows whether certain technical conditions are met; a comprehensive assessment of asset performance should be conducted using additional data. Decisions to trade should not be based solely on this article. Please note that past performance is not indicative of future results.

#HongKongStocks #RealTimeAnalysis #WarrantsSelection #WarrantsStrategy #DerivativesHedging #HongKongWarrantsJenny #WuXiBiologics #02269 #BiotechStocks #TechnicalAnalysis

126K Views